首页> 外文期刊>Journal of Pain Research >Long-term clinical benefit and cost-effectiveness of an 8-week multimodal knee osteoarthritis management program incorporating intra-articular sodium hyaluronate (Hyalgan face='arial, sans-serif' color='#222222'>?) injections
【24h】

Long-term clinical benefit and cost-effectiveness of an 8-week multimodal knee osteoarthritis management program incorporating intra-articular sodium hyaluronate (Hyalgan face='arial, sans-serif' color='#222222'>?) injections

机译:结合关节内透明质酸钠的8周多模式膝关节骨关节炎管理计划的长期临床收益和成本效益(Hyalgan face =“ arial,sans-serif” color =“#222222”> ?< / sup> )注入

获取原文
           

摘要

Background: Given the poor long-term effectiveness of focused nonsurgical knee osteoarthritis (OA) treatments, alternative therapies are needed for patients who have unsuccessfully exhausted nonsurgical options. Methods: A telephone interview was conducted in patients who participated in a single 8-week multimodal knee OA treatment program (mean follow-up: 3.7 years, range: 2.7–4.9 years). The program consisted of five intra-articular knee injections of sodium hyaluronate (Hyalgan?), with each injection given 1 week apart, structured physical therapy, knee bracing, and patient education. Clinical outcomes included knee pain severity, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) subscores, current medication use, and history of total knee arthroplasty. Base-case, subgroup, and sensitivity analyses were conducted to determine the incremental cost-effectiveness ratio (ICER) of the treatment program with comparisons made to historical literature controls undergoing usual care. Results: A total of 218 patients (54%) provided long-term follow-up data. Knee pain severity decreased 60% and WOMAC subscores decreased 33%–42% compared to baseline (all p <0.001). Total knee arthroplasty was performed in 22.8% (81/356) of knees during follow-up. The treatment program was highly cost-effective compared to usual care with a base-case ICER of $6,000 per quality-adjusted life year (QALY). Results of subgroup analyses, one-way deterministic sensitivity analyses, and second-order probabilistic sensitivity analyses resulted in ICERs ranging from $3,996 to $10,493 per QALY. The percentage of simulations with an ICER below willingness-to-pay limits was 97.2%, 98.9%, and 99.4% for the $50,000, $100,000, and $150,000 per QALY thresholds, respectively. Conclusion: Participation in a single 8-week knee OA treatment program, which included one cycle of five intra-articular knee injections of sodium hyaluronate given at weekly intervals, is highly cost-effective and provides clinically meaningful reductions in patient symptoms that are maintained over 3.7 years mean follow-up.
机译:背景:由于集中的非手术性膝骨关节炎(OA)治疗的长期效果不佳,对于用尽非手术选择失败的患者,需要替代疗法。方法:对参加一个为期8周的多模式膝OA治疗计划的患者进行了电话采访(平均随访时间:3.7年,范围:2.7-4.9年)。该程序包括五次关节内膝关节注射透明质酸钠(Hyalgan ?),每次注射间隔1周,进行结构化物理治疗,护膝和患者教育。临床结果包括膝关节疼痛的严重程度,西安大略省和麦克马斯特大学骨关节炎指数(WOMAC)评分,当前用药情况以及全膝关节置换术的历史。进行了基础病例,亚组和敏感性分析,以确定治疗方案的增量成本效益比(ICER),并与接受常规护理的历史文献对照进行了比较。结果:总共218例患者(54%)提供了长期随访数据。与基线相比,膝关节疼痛的严重程度降低了60%,WOMAC评分降低了33%–42%(所有p <0.001)。在随访期间,全膝关节置换术在22.8%(81/356)的膝盖中进行。与常规护理相比,该治疗计划具有很高的成本效益,基础案例的ICER为每质量调整生命年(QALY)$ 6,000。亚组分析,单向确定性敏感性分析和二阶概率敏感性分析的结果表明,每个QALY的ICER范围为$ 3,996至$ 10,493。对于每个QALY阈值50,000美元,100,000美元和150,000美元,ICER低于支付意愿限制的模拟百分比分别为97.2%,98.9%和99.4%。结论:参加一个为期8周的膝盖OA治疗计划,包括一个周期(每周间隔5次关节内膝关节注射透明质酸钠的注射),具有很高的成本效益,并且可以在临床上减轻患者的症状,并且这种症状可以持续平均随访3。7年。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号